While animal models of ALS benefit from rapamycin treatment, future exploration of TBK1 function in neuroprotective autophagy may provide more targeted therapeutic options for these diseases via selective autophagy modulation. Here, TBK1 is linked to amyotrophic lateral sclerosis.